DE60234995D1 - Tatakrebs - Google Patents

Tatakrebs

Info

Publication number
DE60234995D1
DE60234995D1 DE60234995T DE60234995T DE60234995D1 DE 60234995 D1 DE60234995 D1 DE 60234995D1 DE 60234995 T DE60234995 T DE 60234995T DE 60234995 T DE60234995 T DE 60234995T DE 60234995 D1 DE60234995 D1 DE 60234995D1
Authority
DE
Germany
Prior art keywords
risk
calcium
cancer
prostate
tata
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234995T
Other languages
English (en)
Inventor
John A Baron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College filed Critical Dartmouth College
Application granted granted Critical
Publication of DE60234995D1 publication Critical patent/DE60234995D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60234995T 2001-02-16 2002-02-14 Tatakrebs Expired - Lifetime DE60234995D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26925601P 2001-02-16 2001-02-16
PCT/US2002/005214 WO2002066065A1 (en) 2001-02-16 2002-02-14 Calcium supplementation to reduce prostate cancer risk

Publications (1)

Publication Number Publication Date
DE60234995D1 true DE60234995D1 (de) 2010-02-25

Family

ID=23026481

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234995T Expired - Lifetime DE60234995D1 (de) 2001-02-16 2002-02-14 Tatakrebs

Country Status (15)

Country Link
EP (1) EP1365810B1 (de)
CN (1) CN1267154C (de)
AT (1) ATE454168T1 (de)
AU (1) AU2002248474B2 (de)
CA (1) CA2438426C (de)
CY (1) CY1109852T1 (de)
DE (1) DE60234995D1 (de)
DK (1) DK1365810T3 (de)
ES (1) ES2337660T3 (de)
IL (2) IL157408A0 (de)
MX (1) MXPA03007307A (de)
NZ (1) NZ527609A (de)
PT (1) PT1365810E (de)
WO (1) WO2002066065A1 (de)
ZA (1) ZA200306470B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005022953A1 (de) * 2005-05-19 2006-11-23 Chemische Fabrik Budenheim Kg Nahrungsergänzungsmittel
KR101683635B1 (ko) 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5886012A (en) * 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers

Also Published As

Publication number Publication date
NZ527609A (en) 2004-04-30
CN1267154C (zh) 2006-08-02
ZA200306470B (en) 2004-02-10
IL157408A (en) 2010-12-30
IL157408A0 (en) 2004-03-28
MXPA03007307A (es) 2005-02-14
ES2337660T3 (es) 2010-04-28
AU2002248474B2 (en) 2007-04-26
PT1365810E (pt) 2010-03-22
EP1365810B1 (de) 2010-01-06
CA2438426A1 (en) 2002-08-29
WO2002066065A1 (en) 2002-08-29
CN1531443A (zh) 2004-09-22
ATE454168T1 (de) 2010-01-15
CA2438426C (en) 2011-03-15
CY1109852T1 (el) 2014-09-10
EP1365810A1 (de) 2003-12-03
DK1365810T3 (da) 2010-05-10
EP1365810A4 (de) 2004-08-11

Similar Documents

Publication Publication Date Title
EG25822A (en) Quinolinyl-pyrrolopyrazoles
GB0001309D0 (en) Valve arrangement
ZA200203431B (en) Therapeutic use.
EA200001044A2 (ru) Соединения для лечения женской сексуальной дисфункции
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
IL155781A0 (en) Effective antitumor treatments
PL365285A1 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
PT1030667E (pt) Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
HK1048944A1 (en) Use of docetaxel in the manufacture of a medicament for use in the treatment of hepatocellar carcinoma.
CY1109852T1 (el) Συμπληρωμα ασβεστιου για τον περιορισμο του κινδυνου καρκινου του προστατη
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
ID26965A (id) Obat untuk mencegah dan/atau mengobati kanker payudara, yang mengandung inhibitor aromatase steroid
IL159770A0 (en) Calcium salts with cytotoxic activity
MXPA03006359A (es) Metodo para tratamiento del cancer.
NZ337048A (en) Use of N-[1-methyl-(substituted phenyl)ethyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide derivatives to treat prostate cancer
AU2002226004A1 (en) Use of factor xiii for treating hemophilia b
UA38479A (uk) Спосіб моделювання остеопорозу
RU99102760A (ru) Способ лечения рака тела матки
EP1385497A4 (de) Verfahren zur prävention oder behandlung von brust-, prostata- und/oder gebärmutterhalskrebs mit n,n-dimethylglycin
MX9709683A (es) Uso de derivados de vitamina d4 para tratamiento contra el cancer.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition